Literature DB >> 22949050

Lenalidomide maintenance in myeloma.

Alessandro Gozzetti, Marzia Defina, Monica Bocchia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22949050     DOI： 10.1038/nrclinonc.2012.100-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2012-06-05       Impact factor: 66.675

2.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Authors:  Joaquin Martinez-Lopez; Joan Blade; María-Victoria Mateos; Carlos Grande; Adrián Alegre; José García-Laraña; Anna Sureda; Javier de la Rubia; Eulogio Conde; Rafael Martinez; Felipe de Arriba; Maria C Viguria; Joan Besalduch; Rafael Cabrera; José D Gonzalez-San Miguel; José Luis Guzman-Zamudio; Maria Carmen Gomez del Castillo; José Maria Moraleda; Juan C García-Ruiz; Jesús San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

3.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

4.  Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Authors:  M A Dimopoulos; C Chen; A Spencer; R Niesvizky; M Attal; E A Stadtmauer; M T Petrucci; Z Yu; M Olesnyckyj; J B Zeldis; R D Knight; D M Weber
Journal:  Leukemia       Date:  2009-07-23       Impact factor: 11.528

5.  Reappraisal of plateau phase in myeloma.

Authors:  B G Durie; D H Russell; S E Salmon
Journal:  Lancet       Date:  1980-07-12       Impact factor: 79.321

6.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Authors:  Antonio Palumbo; Roman Hajek; Michel Delforge; Martin Kropff; Maria Teresa Petrucci; John Catalano; Heinz Gisslinger; Wiesław Wiktor-Jędrzejczak; Mamia Zodelava; Katja Weisel; Nicola Cascavilla; Genadi Iosava; Michele Cavo; Janusz Kloczko; Joan Bladé; Meral Beksac; Ivan Spicka; Torben Plesner; Joergen Radke; Christian Langer; Dina Ben Yehuda; Alessandro Corso; Lindsay Herbein; Zhinuan Yu; Jay Mei; Christian Jacques; Meletios A Dimopoulos
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

7.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Gerald Marit; Denis Caillot; Philippe Moreau; Thierry Facon; Anne Marie Stoppa; Cyrille Hulin; Lofti Benboubker; Laurent Garderet; Olivier Decaux; Serge Leyvraz; Marie-Christiane Vekemans; Laurent Voillat; Mauricette Michallet; Brigitte Pegourie; Charles Dumontet; Murielle Roussel; Xavier Leleu; Claire Mathiot; Catherine Payen; Hervé Avet-Loiseau; Jean-Luc Harousseau
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

8.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245
  8 in total
  1 in total

Review 1.  Therapeutic advancements in multiple myeloma.

Authors:  Alessandro Gozzetti; Veronica Candi; Giulia Papini; Monica Bocchia
Journal:  Front Oncol       Date:  2014-09-04       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.